Psychiatric conditions often complicate the outcome of patients affected by Parkinson disease (PD), but they differ from classical psychiatric disorders in terms of underlying biological mechanisms, clinical presentation, and treatment response. The purpose of the present review is to illustrate the biological and clinical aspects of psychiatric conditions associated with PD, with particular reference to the differences with respect to classical psychiatric disorders. A careful search of articles on main databases was performed in order to obtain a comprehensive review about the main psychiatric conditions associated with PD. A manual selection of the articles was then performed in order to consider only those articles that concerned with the topic of the review. Psychiatric conditions in patients with PD present substantial differences with respect to classical psychiatric disorders. Their clinical presentation does not align with the symptom profiles represented by Diagnostic and Statistical Manual for Mental Disorders and International Classification of Diseases. Furthermore, psychiatry treatment guidelines are of poor help in managing psychiatric symptoms of patients with PD. Specific diagnostic tools and treatment guidelines are needed to allow early diagnosis and adequate treatment of psychiatric conditions in comorbidity with PD.
GoetzCGPalG. Initial management of Parkinson’s disease. BMJ. 2014;349:g6258.
2.
StarksteinSEBrockmanSHayhowBD. Psychiatric syndromes in Parkinson’s disease. Curr Opin Psychiatry. 2012;25(6):468–472.
3.
GefvertOLindströmLHWatersNWatersSCarlssonATedroffJ. Different corticostriatal patterns of L-DOPA utilization in patients with untreated schizophrenia and patients treated with classical antipsychotics or clozapine. Scand J Psychol. 2003;44(3):289–292.
4.
ParkHKKimJSImKC. Visual hallucinations and cognitive impairment in Parkinson’s disease. Can J Neurol Sci. 2013;40(5):657–662.
5.
AltamuraACBertoldoAMarottaG. White matter metabolism differentiates schizophrenia and bipolar disorder: a preliminary PET study. Psychiatry Res. 2013;214(3):410–414.
6.
LenkaAJhunjhunwalaKRSainiJPalPK. Structural and functional neuroimaging in patients with Parkinson’s disease and visual hallucinations: a critical review. Parkinsonism Relat Disord. 2015;21(7):683–691.
7.
KuberaKMSambataroFVasicN. Source-based morphometry of gray matter volume in patients with schizophrenia who have persistent auditory verbal hallucinations. Prog Neuropsychopharmacol Biol Psychiatry. 2014;50:102–109.
8.
AltamuraACBuoliMCaldiroliA. Misdiagnosis, duration of untreated illness (DUI) and outcome in bipolar patients with psychotic symptoms: A naturalistic study. J Affect Disord. 2015;182:70–75.
9.
MathewIGardinTMTandonN. Medial temporal lobe structures and hippocampal subfields in psychotic disorders: findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study. JAMA Psychiatry. 2014;71(7):769–777
10.
TostHRufMSchmälC. Prefrontal-temporal gray matter deficits in bipolar disorder patients with persecutory delusions. J Affect Disord. 2010;120(1-3):54–61.
11.
OguruMTachibanaHTodaKOkudaBOkaN. Apathy and depression in Parkinson disease. J Geriatr Psychiatry Neurol. 2010;23(1):35–41.
12.
ChyzhykDGrañaMÖngürDShinnAK. Discrimination of schizophrenia auditory hallucinators by machine learning of resting-state functional MRI. Int J Neural Syst. 2015;25(3):1550007.
13.
FénelonGGoetzCGKarenbergA. Hallucinations in Parkinson disease in the prelevodopa era. Neurology. 2006;66(1):93–98.
14.
MackJRabinsPAndersonK. Prevalence of psychotic symptoms in a community-based Parkinson disease sample. Am J Geriatr Psychiatry. 2012;20(2):123–132.
LeeAHWeintraubD. Psychosis in Parkinson’s disease without dementia: common and comorbid with other non-motor symptoms. Mov Disord. 2012;27(7):858–863.
17.
McAuleyJHGregoryS. Prevalence and clinical course of olfactory hallucinations in idiopathic Parkinson’s disease. J Parkinsons Dis. 2012;2(3):199–205.
18.
GeorgievDDanieliAOcepekL. Othello syndrome in patients with Parkinson’s disease. Psychiatr Danub. 2010;22(1):94–78.
19.
YoritakaAShimoYTakanashiM. Motor and non-motor symptoms of 1453 patients with Parkinson’s disease: prevalence and risks. Parkinsonism Relat Disord. 2013;19(8):725–731.
20.
MarshLWilliamsJRRoccoMGrillSMunroCDawsonTM. Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology. 2004;63(2):293–300.
21.
KiziltanGOzekmekçiSErtanSErtanTErginözE. Relationship between age and subtypes of psychotic symptoms in Parkinson’s disease. J Neurol. 2007;254(4):448–452.
22.
FeldmanBChapmanJKorczynAD. Apolipoprotein epsilon4 advances appearance of psychosis in patients with Parkinson’s disease. Acta Neurol Scand. 2006;113(1):14–17.
23.
GoetzCGBurkePFLeurgansS. Genetic variation analysis in parkinson disease patients with and without hallucinations: case-control study. Arch Neurol. 2001;58(2):209–213.
24.
CamicioliRRajputARajputM. Apolipoprotein E epsilon4 and catechol-O-methyltransferase alleles in autopsy-proven Parkinson’s disease: relationship to dementia and hallucinations. Mov Disord. 2005;20(8):989–994.
25.
SawadaHOedaTUmemuraA. Subclinical elevation of plasma C-reactive protein and illusions/hallucinations in subjects with Parkinson’s disease: case-control study. PLoS One. 2014;9(1):e85886.
26.
PagonabarragaJSoriano-MasCLlebariaGLópez-SolàMPujolJKulisevskyJ. Neural correlates of minor hallucinations in non-demented patients with Parkinson’s disease. Parkinsonism Relat Disord. 2014;20(3):290–296.
27.
LewisSJShineJMDuffySHallidayGNaismithSL. Anterior cingulate integrity: executive and neuropsychiatric features in Parkinson’s disease. Mov Disord. 2012;27(10):1262–1267.
28.
BallangerBStrafellaAPvan EimerenT. Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol. 2010;67(4):416–421.
29.
KiferleLCeravoloRPetrozziL. Visual hallucinations in Parkinson’s disease are not influenced by polymorphisms of serotonin 5-HT2A receptor and transporter genes. Neurosci Lett. 2007;422(3):228–231.
30.
LinJJYuehKCLinSZHarnHJLiuJT. Genetic polymorphism of the angiotensin converting enzyme and L-dopa-induced adverse effects in Parkinson’s disease. J Neurol Sci. 2007;252(2):130–134.
31.
AarslandDLarsenJPCumminsJLLaakeK. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol. 1999;56(5):595–601.
32.
PacchettiCManniRZangagliaR. Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson’s disease. Mov Disord. 2005;20(11):1439–1448.
33.
WeintraubDHurtigHI. Presentation and management of psychosis in Parkinson’s disease and dementia with Lewy bodies. Am J Psychiatry. 2007;164(10):1491–1498.
34.
ForsaaEBLarsenJPWentzel-LarsenT. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol. 2010;67(8):996–1001.
35.
FactorSASteenlandNKHigginsDS. Disease-related and genetic correlates of psychotic symptoms in Parkinson’s disease. Mov Disord. 2011;26(12):2190–2195.
36.
MorganteLColosimoCAntoniniA. Psychosis associated to Parkinson’s disease in the early stages: relevance of cognitive decline and depression. J Neurol Neurosurg Psychiatry. 2012;83(1):76–82.
37.
CohenOSVakilETanneDNitsanZSchwartzRHassin-BaerS. Educational level as a modulator of cognitive performance and neuropsychyatric features in Parkinson disease. Cogn Behav Neurol. 2007;20(1):68–72.
38.
LlebariaGPagonabarragaJMartínez-CorralM. Neuropsychological correlates of mild to severe hallucinations in Parkinson’s disease. Mov Disord. 2010;25(16):2785–2791.
39.
SuetaniSFooEWilsonD. De novo psychosis in a new onset Parkinson disease. Aust N Z J Psychiatry. 2014;48(3):292–293.
40.
ForsaaEBLarsenJPWentzel-LarsenTAlvesG. What predicts mortality in Parkinson disease?: a prospective population-based long-term study. Neurology. 2010;75(14):1270–1276.
41.
de LauLMVerbaanDMarinusJvan HiltenJJ. Survival in Parkinson’s disease. Relation with motor and non-motor features. Parkinsonism Relat Disord. 2014;20(6):613–616.
42.
AuyeungMTsoiTHMokV. Ten year survival and outcomes in a prospective cohort of new onset Chinese Parkinson’s disease patients. J Neurol Neurosurg Psychiatry. 2012;83(6):607–611.
43.
NazemSSiderowfADDudaJE. Suicidal and death ideation in Parkinson’s disease. Mov Disord. 2008;23(11):1573–1579.
44.
WoltersECHurwitzTAMakE. Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology. 1990;40(5):832–834.
45.
The French Clozapine Parkinson Study Group. Clozapine in drug-induced psychosis in Parkinson’s disease. Lancet. 1999;353(9169):2041–2042.
46.
The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. N Engl J Med. 1999;340(10):757–763.
47.
PollakPTisonFRascolO. Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry. 2004;75(5):689–695.
48.
EllisTCudkowiczMESextonPMGrowdonJH. Clozapine and risperidone treatment of psychosis in Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 2000;12(3):364–369.
49.
BreierASuttonVKFeldmanPD. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s disease. Biol Psychiatry. 2002;52(5):438–445.
50.
OndoWGLevyJKVuongKDHunterCJankovicJ. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord. 2002;17(5):1031–1035.
51.
GoetzCGBlasucciLMLeurgansSPappertEJ. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology. 2000;55(6):789–794.
52.
OndoWGTintnerRVoungKDLaiDRingholzG. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson’s disease. Mov Disord. 2005;20(8):958–963.
53.
RabeyJMProkhorovTMiniovitzADobronevskyEKleinC. Effect of quetiapine in psychotic Parkinson’s disease patients: a double-blind labeled study of 3 months’ duration. Mov Disord. 2007;22(3):313–318.
54.
FernandezHHOkunMSRodriguezRL. Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography study. Int J Neurosci. 2009;119(12):2196–205.
55.
BergmanJLernerV. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson’s disease. Clin Neuropharmacol. 2002;25(2):107–110.
56.
FabbriniGBarbantiPAuriliaCPaulettiCLenziGLMecoG. Donepezil in the treatment of hallucinations and delusions in Parkinson’s disease. Neurol Sci. 2002;23(1):41–43.
57.
KuritaAOchiaiYKonoYSuzukiMInoueK. The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson’s disease. J Geriatr Psychiatry Neurol. 2003;16(3):184–188.
58.
SobowT. Parkinson’s disease-related visual hallucinations unresponsive to atypical antipsychotics treated with cholinesterase inhibitors: a case series. Neurol Neurochir Pol. 2007;41(3):276–279.
59.
ReadingPJLuceAKMcKeithIG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord. 2001;16(6):1171–1174.
60.
BullockRCameronA. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson’s disease: a case series. Curr Med Res Opin. 2002;18(5):258–264.
61.
IkeguchiKKurodaA. Mianserin treatment of patients with psychosis induced by antiparkinsonian drugs. Eur Arch Psychiatry Clin Neurosci. 1995;244(6):320–324.
62.
FactorSAMolhoESBrownDL. Combined clozapine and electroconvulsive therapy for the treatment of drug-induced psychosis in Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 1995;7(3):304–307.
63.
UedaSKoyamaKOkuboY. Marked improvement of psychotic symptoms after electroconvulsive therapy in Parkinson disease. J ECT. 2010;26(2):111–115.
64.
MuralidharanKThimmaiahRChakrabortyVJainS. Bifrontal ECT for drug-induced psychosis in Parkinson’s disease. Indian J Psychiatry. 2011;53(2):156–158.
65.
UsuiCHattaKDoiN. Improvements in both psychosis and motor signs in Parkinson’s disease, and changes in regional cerebral blood flow after electroconvulsive therapy. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(7):1704–1708.
66.
UmemuraAOkaYOkitaKMatsukawaNYamadaK. Subthalamic nucleus stimulation for Parkinson disease with severe medication-induced hallucinations or delusions. J Neurosurg. 2011;114(6):1701–1705.
67.
AltamuraACSeratiMBuoliM. Is duration of illness really influencing outcome in major psychoses?Nord J Psychiatry. 2015;69(6):403–417.
68.
AltamuraACBuoliMPozzoliS. Role of immunological factors in the pathophysiology and diagnosis of bipolar disorder: comparison with schizophrenia. Psychiatry Clin Neurosci. 2014;68(1):21–36.
69.
BuoliMCaldiroliAPanzaGAltamuraAC. Prominent clinical dimension, duration of illness and treatment response in schizophrenia: a naturalistic study. Psychiatry Investig. 2012;9(4):354–360.
70.
RybakowskiJKVansteelandtKRemlinger-MolendaAFleischhackerWWKahnRSPeuskensJ; EUFEST Study Group. Extrapyramidal symptoms during treatment of first schizophrenia episode: results from EUFEST. Eur Neuropsychopharmacol. 2014;24(9):1500–1505.
71.
DoldMLeuchtS. Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective. Evid Based Ment Health. 2014;17(2):33–37.
72.
BeasleyCMJrSangerTSatterleeWTollefsonGTranPHamiltonS. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl). 1996;124(1-2):159–167.
73.
PetridesGMalurCBragaRJ. Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study. Am J Psychiatry. 2015;172(1):52–58.
74.
RiedelOHeuserIKlotscheJDodelRWittchenHU; GEPAD Study Group. Occurrence risk and structure of depression in Parkinson disease with and without dementia: results from the GEPAD Study. J Geriatr Psychiatry Neurol. 2010;23(1):27–34.
75.
GoCLRosalesRLJoya-TanglaoMFernandezHH. Untreated depressive symptoms among cognitively-intact, community dwelling Filipino patients with Parkinson disease. Int J Neurosci. 2011;121(3):137–141.
76.
BeckerCBrobertGPJohanssonSJickSSMeierCR. Risk of incident depression in patients with Parkinson disease in the UK. Eur J Neurol. 2011;18(3):448–453.
77.
LeentjensAFMarinusJVan HiltenJJLousbergRVerheyFR. The contribution of somatic symptoms to the diagnosis of depressive disorder in Parkinson’s disease: a discriminant analytic approach. J Neuropsychiatry Clin Neurosci. 2003;15(1):74–77.
78.
AlvesGWentzel-LarsenTLarsenJP. Is fatigue an independent and persistent symptom in patients with Parkinson disease?Neurology. 2004;63(10):1908–1911.
79.
MatsuiKTachibanaHYamanishiT. Clinical correlates of anhedonia in patients with Parkinson’s disease. Clin Neurol Neurosurg. 2013;115(12):2524–2527.
80.
RichardIHFrankSMcDermottMP. The ups and downs of Parkinson disease: a prospective study of mood and anxiety fluctuations. Cogn Behav Neurol. 2004;17(4):201–207.
81.
O’SuilleabhainPESungVHernandezC. Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. Arch Neurol. 2004;61(6):865–868.
82.
SuzukiKMiyamotoTMiyamotoMKajiYTakekawaHHirataK. Circadian variation of core body temperature in Parkinson disease patients with depression: a potential biological marker for depression in Parkinson disease. Neuropsychobiology. 2007;56(4):172–179.
83.
MeyerPMStreckerKKendziorraK. Reduced alpha4beta2*-nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease. Arch Gen Psychiatry. 2009;66(8):866–877.
84.
KostićVSAgostaFPetrovićI. Regional patterns of brain tissue loss associated with depression in Parkinson disease. Neurology. 2010;75(10):857–863.
85.
LiWLiuJSkidmoreFLiuYTianJLiK. White matter microstructure changes in the thalamus in Parkinson disease with depression: a diffusion tensor MR imaging study. Am J Neuroradiol. 2010;31(10):1861–1866.
86.
HuaPLiuWKuoSH. Association of Tef polymorphism with depression in Parkinson disease. Mov Disord. 2012;27(13):1694–1697.
87.
LeentjensAFMoonenAJDujardinK. Modeling depression in Parkinson disease: disease-specific and nonspecific risk factors. Neurology. 2013;81(12):1036–1043.
88.
TandbergELarsenJPAarslandDLaakeKCummingsJL. Risk factors for depression in Parkinson disease. Arch Neurol. 1997;54(5):625–630.
89.
KlepacNTrkuljaVReljaM. Nondemented Parkinson disease patients: is cognitive performance associated with depressive difficulties?Cogn Behav Neurol. 2008;21(2):87–91.
90.
DeweyRBJrTanejaAMcClintockSMCullumCMDeweyRB3 rdBernsteinIHusainMM. Motor symptoms at onset of Parkinson disease and risk for cognitive impairment and depression. Cogn Behav Neurol. 2012;25(3):115–120.
91.
EhrtULarsenJPAarslandD. Pain and its relationship to depression in Parkinson disease. Am J Geriatr Psychiatry. 2009;17(4):269–275.
92.
AbrantesAMFriedmanJHBrownRAStrongDRDesaulniersJIngESaritelliJRiebeD. Physical activity and neuropsychiatric symptoms of Parkinson disease. J Geriatr Psychiatry Neurol. 2012;25(3):138–145.
93.
HolroydSCurrieLJWootenGF. Depression is associated with impairment of ADL, not motor function in Parkinson disease. Neurology. 2005;64(12):2134–2135.
94.
RavinaBCamicioliRComoPG. The impact of depressive symptoms in early Parkinson disease. Neurology. 2007;69(4):342–347.
95.
KummerAHarsányiEDiasFMCardosoFCaramelliPTeixeiraAL. Depression impairs executive functioning in Parkinson disease patients with low educational level. Cogn Behav Neurol. 2009;22(3):167–172.
96.
KlepacNHajnsekSTrkuljaV. Cognitive performance in nondemented nonpsychotic Parkinson disease patients with or without a history of depression prior to the onset of motor symptoms. J Geriatr Psychiatry Neurol. 2010;23(1):15–26.
97.
HerzallahMMMoustafaAAMiskAJ. Depression impairs learning whereas anticholinergics impair transfer generalization in Parkinson patients tested on dopaminergic medications. Cogn Behav Neurol. 2010;23(2):98–105.
98.
FernandezHHSeeRHGaryMF. Depressive symptoms in Parkinson disease correlate with impaired global and specific cognitive performance. J Geriatr Psychiatry Neurol. 2009;22(4):223–227.
99.
RabeyJMOrlovEKorczynAD. Comparison of Fluvoxamine versus Amitriptyline for treatment of depression in Parkinson’s disease. Neurology. 1996;46:A374.
100.
WermuthLSorensenPSTimmSE. Depression in idiopathic Parkinson’s disease treated with citalopram: a placebo-controlled trial. Nord J Psychiatry. 1998;52(2):163–169.
101.
LeentjensAFVreelingFWLuijckxGJVerheyFR. SSRIs in the treatment of depression in Parkinson’s disease. Int J Geriatr Psychiatry. 2003;18(6):552–554.
102.
AntoniniATeseiSZecchinelliA. Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson’s disease and depression: effect on quality of life. Mov Disord. 2006; 21(8):1119–1122.
103.
ÁvilaCardona XMartin-BaraneraMMahoPSastreFBelloJ. Does nefazodone improve both depression and Parkinson disease?A pilot randomized trial. J Clin Psychopharmacol. 2003;23(5):509–513.
104.
MenzaMDobkinRDMarinH. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology. 2009;72(10):886–892.
105.
DevosDDujardinKPoirotI. Comparison of desipramine and citalopram treatments for depression in Parkinson’s disease: a double-blind, randomized, placebo-controlled study. Mov Disord. 2008;23(6):850–857.
106.
RichardIHMcDermottMPKurlanR. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology. 2012;78(16):1229–1236.
107.
da SilvaTMMunhozRPAlvarezCNaliwaikoKKissAAndreatiniRFerrazAC. Depression in Parkinson’s disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation. J Affect Disord. 2008;111(2-3):351–359.
108.
WeintraubDMavandadiSMamikonyanE. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology. 2010;75(5):448–455.
109.
RektorovaIBalazMSvatovaJ. Effects of ropinirole on nonmotor symptoms of Parkinson disease: a prospective multicenter study. Clin Neuropharmacol. 2008;31(5):261–266.
110.
RektorováIRektorIBaresM. Pramipexole and pergolide in the treatment of depression in Parkinson’s disease: a national multicentre prospective randomized study. Eur J Neurol. 2003;10(4):399–406.
111.
BaronePPoeweWAlbrechtS. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(6):573–580.
112.
DobkinRDMenzaMAllenLA. Telephone-based cognitive-behavioral therapy for depression in Parkinson disease. J Geriatr Psychiatry Neurol. 2011;24(4):206–214.
113.
BailineSKremenNKohenI. Bitemporal electroconvulsive therapy for depression in a Parkinson disease patient with a deep-brain stimulator. J ECT. 2008;24(2):171–172.
114.
ChopraATyeSJLeeKH. Voltage-dependent mania after subthalamic nucleus deep brain stimulation in Parkinson’s disease: a case report. Biol Psychiatry. 2011;70(2):e5–e7.
115.
MaierFMerklJEllereitAL. Hypomania and mania related to dopamine replacement therapy in Parkinson’s disease. Parkinsonism Relat Disord. 2014;20(4):421–427.
116.
HarschHHMillerrMYpungLD. Induction of mania by L-dopa in a nonbipolar patient. J Clin Psychopharmacol. 1985;5(6):338–339.
117.
SaitoSShiodaKNishijimaK. Dopamine dysregulation syndrome including mania related to coadministration of droxidopa. J Clin Psychopharmacol. 2012;32(3):428–429.
118.
KurlanRDimitsopulosT. Selegiline and manic behaviour in Parkinson’s disease. Arch Neurol. 1992;49(12):1231.
119.
PrzedborskiSLiardAHildebrandJ. Induction of mania by apomorphine in a depressed parkinsonian patient. Mov Disord. 1992;7(3):285–287.
120.
EngmannB. Bipolar affective disorder and Parkinson’s disease. Case Rep Med. 2011;2011:154165.
121.
CannasASpissuAFlorisGL. Bipolar affective disorder and Parkinson’s disease: a rare, insidious and often unrecognized association. Neurol Sci. 2002;23(suppl 2):67–68.
122.
ChopraATyeSJLeeKH. Underlying neurobiology and clinical correlates of mania status after subthalamic nucleus deep brain stimulation in Parkinson’s disease: a review of the literature. J Neuropsychiatry Clin Neurosci. 2012;24(1):102–110.
123.
UgurluTTAcarGKaradagFAcarF. Manic episode following deep brain stimulation of the subthalamic nucleus for Parkinson’s disease: a case report. Turk Neurosurg. 2014;24(1):94–97.
124.
KulisevskyJBerthierMLGironellAPascual-SedanoBMoletJParésP. Mania following deep brain stimulation for Parkinson’s disease. Neurology. 2002;59(9):1421–1424.
125.
Visser-VandewalleVvan der LindenCTemelY. Long-term effects of bilateral subthalamic nucleus stimulation in advanced Parkinson disease: a four year follow-up study. Parkinsonism Relat Disord. 2005;11(3):157–165.
126.
MandatTSHurwitzTHoneyCR. Hypomania as an adverse effect of subthalamic nucleus stimulation: report of two cases. Acta Neurochir (Wien). 2006;148(8):895–897.
127.
RomitoLMRajaMDanieleA. Transient mania with hypersexuality after surgery for high frequency stimulation of the subthalamic nucleus in Parkinson’s disease. Mov Disord. 2002;17(6):1371–1374.
128.
RomitoLMScerratiMContarinoMFBentivoglioARTonaliPAlbaneseA. Long-term follow up of subthalamic nucleus stimulation in Parkinson’s disease. Neurology. 2002;58(10):1546–1550.
129.
UllaMThoboisSLlorcaPM. Contact dependent reproducible hypomania induced by deep brain stimulation in Parkinson’s disease: clinical, anatomical and functional imaging study. J Neurol Neurosurg Psychiatry. 2011;82(6):607–614.
130.
UllaMThoboisSLemaireJJ. Manic behaviour induced by deep-brain stimulation in Parkinson’s disease: evidence of substantia nigra implication?J Neurol Neurosurg Psychiatry. 2006;77(12):1363–1366.
131.
Raucher-ChénéDCharrelCLde MaindrevilleADLimosinF. Manic episode with psychotic symptoms in a patient with Parkinson’s disease treated by subthalamic nucleus stimulation: improvement on switching the target. J Neurol Sci. 2008;273(1-2):116–117.
132.
KimEZwilASMcAllisterTWGlosserDSSternMHurtigH. Treatment of organic bipolar mood disorders in Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 1994;6(2):181–184.
133.
HerzogJReiffJKrackP. Manic episode with psychotic symptoms induced by subthalamic nucleus stimulation in a patient with Parkinson’s disease. Mov Disord. 2003;18(11):1382–1384.
134.
ThomasNJebarajPKishor KumarS. Bipolar affective disorder in Parkinson’s disease: clinical dilemmas. Indian J Med Sci. 2008;62(9):374–376.
135.
SinghAAlthoffRMartineauRJJacobsonJ. Pramipexole, ropinirole, and mania in Parkinson’s disease. Am J Psychiatry. 2005;162(4):814–815.
136.
BerkowitzAL. Ziprasidone therapy in elderly patients with psychotic mood disorders and Parkinson’s disease. Psychiatry (Edgmont). 2006;3(11):59–63.
137.
KesslerRCPetukhovaMSampsonNAZaslavskyAMWittchenHU. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res. 2012;21(3):169–184.
138.
RamasubbuRKonduruNCorteseFBraySGaxiola-ValdezIGoodyearB. Reduced intrinsic connectivity of amygdala in adults with major depressive disorder. Front Psychiatry. 2014;5:17.
139.
BauneBTMillerRMcAfooseJJohnsonMQuirkFMitchellD. The role of cognitive impairment in general functioning in major depression. Psychiatry Res. 2010;176(2-3):183–189.
140.
LiuJDongJWangLSuYYanPSunS. Comparative efficacy and acceptability of antidepressants in Parkinson’s disease: a network meta-analysis. PLoS One. 2013;8(10):e76651.
141.
Pomarol-ClotetEAlonso-LanaSMoroN. Brain functional changes across the different phases of bipolar disorder. Br J Psychiatry. 2015;206(2):136–344.
142.
AltamuraACMoliternoDPalettaS. Effect of quetiapine and norquetiapine on anxiety and depression in major psychoses using a pharmacokinetic approach: a prospective observational study. Clin Drug Investig. 2012;32(3):213–219.
143.
IsellaVMelziPGrimaldiM. Clinical, neuropsychological, and morphometric correlates of apathy in Parkinson’s disease. Mov Disord. 2002;17(2):366–371.
144.
ZahodneLBMarsiskeMOkunMSBowersD. Components of depression in Parkinson disease. J Geriatr Psychiatry Neurol. 2012;25(3):131–137.
145.
StarksteinSEMaybergHSPreziosiTJAndrezejewskiPLeiguardaRRobinsonRG. Reliability, validity, and clinical correlates of apathy in Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 1992;4(2):134–139.
146.
PedersenKFLarsenJPAlvesGAarslandD. Prevalence and clinical correlates of apathy in Parkinson’s disease: a community-based study. Parkinsonism Relat Disord. 2009;15(4):295–299.
147.
StarksteinSEMerelloMJorgeRBrockmanSBruceDPowerB. The syndromal validity and nosological position of apathy in Parkinson’s disease. Mov Disord. 2009;24(8):1211–1216.
148.
Kirsch-DarrowLFernandezHHMarsiskeMOkunMSBowersD. Dissociating apathy and depression in Parkinson disease. Neurology. 2006;67(1):33–38.
149.
Kirsch-DarrowLZahodneLBMarsiskeMOkunMSFooteKDBowersD. The trajectory of apathy after deep brain stimulation: from pre-surgery to 6 months post-surgery in Parkinson’s disease. Parkinsonism Relat Disord. 2011;17(3):182–188.
150.
LouisEDHueyEDGerbinMVinerAS. Apathy in essential tremor, dystonia, and Parkinson’s disease: a comparison with normal controls. Mov Disord. 2012;27(3):432–434.
151.
ZiropadjaLjStefanovaEPetrovicMStojkovicTKosticVS. Apathy and depression in Parkinson’s disease: the Belgrade PD study report. Parkinsonism Relat Disord. 2012;18(4):339–342.
152.
SkidmoreFMYangMBaxterL. Apathy, depression, and motor symptoms have distinct and separable resting activity patterns in idiopathic Parkinson disease. Neuroimage. 2013;81:484–495.
153.
ReijndersJSScholtissenBWeberWEAaltenPVerheyFRLeentjensAF. Neuroanatomical correlates of apathy in Parkinson’s disease: A magnetic resonance imaging study using voxel-based morphometry. Mov Disord. 2010;25(14):2318–2325.
154.
RobertGLe JeuneFLozachmeurC. Apathy in patients with Parkinson disease without dementia or depression: a PET study. Neurology. 2012;79(11):1155–1160.
155.
RobertGLe JeuneFDondaineT. Apathy and impaired emotional facial recognition networks overlap in Parkinson’s disease: a PET study with conjunction analyses. J Neurol Neurosurg Psychiatry. 2014;85(10):1153–1158.
156.
Le JeuneFDrapierDBourguignonA. Subthalamic nucleus stimulation in Parkinson disease induces apathy: a PET study. Neurology. 2009;73(21):1746–1751.
157.
LawrenceADGoerendtIKBrooksDJ. Apathy blunts neural response to money in Parkinson’s disease. Soc Neurosci. 2011;6(5-6):653–662.
158.
ReadyREFriedmanJGraceJFernandezH. Testosterone deficiency and apathy in Parkinson’s disease: a pilot study. J Neurol Neurosurg Psychiatry. 2004;75(9):1323–1326.
159.
KenangilGOrkenDNUrEFortaHCelikM. The relation of testosterone levels with fatigue and apathy in Parkinson’s disease. Clin Neurol Neurosurg. 2009;111(5):412–414.
160.
DietzJBradleyMMJonesJOkunMSPerlsteinWMBowersD. The late positive potential, emotion and apathy in Parkinson’s disease. Neuropsychologia. 2013;51(5):960–966.
161.
MathisSNeauJPPluchonC. Apathy in Parkinson’s disease: an electrophysiological study. Neurol Res Int. 2014;2014:290513.
162.
Martínez-HortaSRibaJde BobadillaRF. Apathy in Parkinson’s disease: neurophysiological evidence of impaired incentive processing. J Neurosci. 2014;34(17):5918–5926.
163.
Rodríguez-ViolanteMGonzález-LatapiPCervantes-ArriagaAMartínez-RamírezDVelázquez-OsunaSCamacho-OrdoñezA. Apathy and associated factors in Mexican patients with Parkinson’s disease. Neurol Sci. 2014;35(5):729–734.
164.
LeroiIAndrewsMMcDonaldK. Apathy and impulse control disorders in Parkinson’s disease: a direct comparison. Parkinsonism Relat Disord. 2012;18(2):198–203.
165.
PedersenKFAlvesGBrønnickKAarslandDTysnesOBLarsenJP. Apathy in drug-naïve patients with incident Parkinson’s disease: the Norwegian ParkWest study. J Neurol. 2010;257(2):217–223.
166.
PedersenKFAlvesGAarslandDLarsenJP. Occurrence and risk factors for apathy in Parkinson disease: a 4-year prospective longitudinal study. J Neurol Neurosurg Psychiatry. 2009;80(11):1279–1282.
167.
Sáez-FrancàsNHernández-VaraJCorominas RosoMAlegre MartínJCasas BruguéM. The association of apathy with central fatigue perception in patients with Parkinson’s disease. Behav Neurosci. 2013;127(2):237–244.
168.
SkorvanekMRosenbergerJGdovinovaZ. Apathy in elderly nondemented patients with Parkinson’s disease: clinical determinants and relationship to quality of life. J Geriatr Psychiatry Neurol. 2013;26(4):237–243.
169.
JordanLLZahodneLBOkunMSBowersD. Hedonic and behavioral deficits associated with apathy in Parkinson’s disease: potential treatment implications. Mov Disord. 2013;28(9):1301–1304.
170.
CuboEBenito-LeónJCoronellCArmestoD, ANIMO Study Group. Clinical correlates of apathy in patients recently diagnosed with Parkinson’s disease: the ANIMO study. Neuroepidemiology. 2012;38(1):48–55.
171.
HarrisEMcNamaraPDursoR. Apathy in patients with Parkinson disease as a function of side of onset. J Geriatr Psychiatry Neurol. 2013;26(2):95–104.
172.
MorettiRTorrePAntonelloRM. Apathy: a complex symptom specific to the clinical pattern of presentation of Parkinson’s disease?Am J Alzheimers Dis Other Demen. 2012;27(3):196–201.
173.
ZahodneLBBernal-PachecoOBowersD. Are selective serotonin reuptake inhibitors associated with greater apathy in Parkinson’s disease?J Neuropsychiatry Clin Neurosci. 2012;24(3):326–330.
174.
SantangeloGVitaleCTrojanoL. Relationship between apathy and cognitive dysfunctions in de novo untreated Parkinson’s disease: a prospective longitudinal study. Eur J Neurol. 2015;22(2):253–260.
175.
DrapierDDrapierSSauleauP. Does subthalamic nucleus stimulation induce apathy in Parkinson’s disease?J Neurol. 2006;253(8):1083–1091.
176.
DrapierDPéronJLerayE. Emotion recognition impairment and apathy after subthalamic nucleus stimulation in Parkinson’s disease have separate neural substrates. Neuropsychologia. 2008;46(11):2796–2801.
177.
AntoniniAIsaiasIURodolfiG. A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation. J Neurol. 2011;258(4):579–585.
178.
HiguchiMATsuboiYInoueT. Predictors of the Emergence of Apathy After Bilateral Stimulation of the Subthalamic Nucleus in Patients with Parkinson’s Disease. Neuromodulation. 2015;18(2):113–117.
179.
CzerneckiVPillonBHouetoJL. Does bilateral stimulation of the subthalamic nucleus aggravate apathy in Parkinson’s disease?J Neurol Neurosurg Psychiatry. 2005;76(6):775–779.
180.
LozachmeurCDrapierSRobertG. Pallidal stimulation in Parkinson’s disease does not induce apathy. J Neuropsychiatry Clin Neurosci. 2014;26(3):221–226.
181.
DujardinKSockeelPDelliauxMDestéeADefebvreL. Apathy may herald cognitive decline and dementia in Parkinson’s disease. Mov Disord. 2009;24(16):2391–2397.
182.
HassanAVallabhajosulaSZahodneLB. Correlations of apathy and depression with postural instability in Parkinson disease. J Neurol Sci. 2014;338(1-2):162–165.
183.
ZgaljardicDJBorodJCFoldiNS. Relationship between self-reported apathy and executive dysfunction in nondemented patients with Parkinson disease. Cogn Behav Neurol. 2007;20(3):184–192.
184.
ButterfieldLCCiminoCROelkeLEHauserRASanchez-RamosJ. The independent influence of apathy and depression on cognitive functioning in Parkinson’s disease. Neuropsychology. 2010;24(6):721–730.
185.
VaraneseSPerfettiBGhilardiMFDi RoccoA. Apathy, but not depression, reflects inefficient cognitive strategies in Parkinson’s disease. PLoS One. 2011;6(3):e1784.
186.
BuelowMTFrakeyLLGraceJFriedmanJH. The contribution of apathy and increased learning trials to risky decision-making in Parkinson’s disease. Arch Clin Neuropsychol. 2014;29(1):100–109.
187.
Martínez-CorralMPagonabarragaJLlebariaG. Facial emotion recognition impairment in patients with Parkinson’s disease and isolated apathy. Parkinsons Dis. 2010;2010:930627.
188.
Benito-LeónJCuboECoronellC; ANIMO Study Group. Impact of apathy on health-related quality of life in recently diagnosed Parkinson’s disease: the ANIMO study. Mov Disord. 2012;27(2):211–218.
189.
LaatuSKarraschMMartikainenKMarttilaR. Apathy is associated with activities of daily living ability in Parkinson’s disease. Dement Geriatr Cogn Disord. 2013;35(5-6):249–255.
190.
LeroiIHarbishettarVAndrewsMMcDonaldKByrneEJBurnsA. Carer burden in apathy and impulse control disorders in Parkinson’s disease. Int J Geriatr Psychiatry. 2012;27(2):160–166.
191.
BogdanovaYCronin-GolombA. Alexithymia and apathy in Parkinson’s disease: neurocognitive correlates. Behav Neurol. 2013;27(4):535–545.
192.
DevosDMoreauCMaltêteD. Rivastigmine in apathetic but dementia and depression-free patients with Parkinson’s disease: a double-blind, placebo-controlled, randomised clinical trial. J Neurol Neurosurg Psychiatry. 2014;85(6):668–674.
193.
CzerneckiVSchüpbachMYaiciS. Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom. Mov Disord. 2008;23(7):964–969.
YuenGSGunningFMWoodsEKlimstraSAHoptmanMJAlexopoulosGS. Neuroanatomical correlates of apathy in late-life depression and antidepressant treatment response. J Affect Disord. 2014;166:179–186.
196.
RaskinJGeorgeTGrangerREHussainNZhaoGWMarangellLB. Apathy in currently nondepressed patients treated with a SSRI for a major depressive episode: outcomes following randomized switch to either duloxetine or escitalopram. J Psychiatr Res. 2012;46(5):667–674.
197.
SteinMBHeuserIJJuncosJLUhdeTW. Anxiety disorders in patients with Parkinson’s disease. Am J Psychiatry. 1990;147(2):217–220.
198.
StefanovaEZiropadjaLPetrovićMStojkovićTKostićV. Screening for anxiety symptoms in Parkinson disease: a cross-sectional study. J Geriatr Psychiatry Neurol. 2013;26(1):34–40.
199.
PontoneGMWilliamsJRAndersonKE. Prevalence of anxiety disorders and anxiety subtypes in patients with Parkinson’s disease. Mov Disord. 200915;24(9):1333–1338.
200.
HendersonRKurlanRKersunJMComoP. Preliminary examination of the comorbidity of anxiety and depression in Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 1992;4(3):257–264.
201.
DissanayakaNNSellbachAMathesonS. Anxiety disorders in Parkinson’s disease: prevalence and risk factors. Mov Disord. 2010;25(7):838–845.
202.
BrownRGLandauSHindleJV. Depression and anxiety related subtypes in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2011;82(7):803–809.
203.
MenzaMARobertson-HoffmanDEBonapaceAS. Parkinson’s disease and anxiety: comorbidity with depression. Biol Psychiatry. 1993;34(7):465–470.
204.
PasmanEPMurnaghanCDBloemBRCarpenterMG. Balance problems with Parkinson’s disease: are they anxiety-dependent?Neuroscience. 2011;177:283–291.
205.
FosterPSDragoVCrucianGP. Anxiety and depression severity are related to right but not left onset Parkinson’s disease duration. J Neurol Sci. 2011;305(1-2):131–135.
206.
FlemingerS. Left-sided Parkinson’s disease is associated with greater anxiety and depression. Psychol Med. 1991;21(3):629–638.
207.
BerriosGECampbellCPolitynskaBE. Autonomic failure, depression and anxiety in Parkinson’s disease. Br J Psychiatry. 1995;166(6):789–792.
208.
ChenYKLuJYChanDM. Anxiety disorders in Chinese patients with Parkinson’s disease. Int J Psychiatry Med. 2010;40(1):97–107.
209.
QureshiSUAmspokerABCalleoJSKunikMEMarshL. Anxiety disorders, physical illnesses, and health care utilization in older male veterans with Parkinson disease and comorbid depression. J Geriatr Psychiatry Neurol. 2012;25(4):233–239.
210.
LeentjensAFDujardinKMarshLMartinez-MartinPRichardIHStarksteinSE. Symptomatology and markers of anxiety disorders in Parkinson’s disease: a cross-sectional study. Mov Disord. 2011;26(3):484–492.
211.
LauterbachECFreemanAVogelRL. Correlates of generalized anxiety and panic attacks in dystonia and Parkinson disease. Cogn Behav Neurol. 2003;16(4):225–233.
212.
RichardIHSzegethyELichterDSchifferRBKurlanR. Parkinson’s disease: a preliminary study of yohimbine challenge in patients with anxiety. Clin Neuropharmacol. 1999;22(3):172–175.
213.
BollukBOzel-KizilETAkbostanciMCAtbasogluEC. Social anxiety in patients with Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 2010;22(4):390–394.
214.
GultekinBKOzdilekB2BestepeEE. Social phobia in Parkinson’s disease: Prevalence and risk factors. Neuropsychiatr Dis Treat. 2014;10:829–834.
215.
MoriyamaTSFelicioACChagasMH. Increased dopamine transporter density in Parkinson’s disease patients with Social Anxiety Disorder. J Neurol Sci. 2011;310(1-2):53–57.
216.
ErroRPappatàSAmboniM. Anxiety is associated with striatal dopamine transporter availability in newly diagnosed untreated Parkinson’s disease patients. Parkinsonism Relat Disord. 2012;18(9):1034–1038.
217.
WeisskopfMGChenHSchwarzschildMAKawachiIAscherioA. Prospective study of phobic anxiety and risk of Parkinson’s disease. Mov Disord. 2003;18(6):646–651.
218.
LeentjensAFDujardinKMarshLMartinez-MartinPRichardIHStarksteinSE. Anxiety and motor fluctuations in Parkinson’s disease: a cross-sectional observational study. Parkinsonism Relat Disord. 2012;18(10):1084–1088.
219.
SiemersERShekharAQuaidKDicksonH. Anxiety and motor performance in Parkinson’s disease. Mov Disord. 1993;8(4):501–506.
220.
MaricleRANuttJGCarterJH. Mood and anxiety fluctuation in Parkinson’s disease associated with levodopa infusion: preliminary findings. Mov Disord. 1995;10(3):329–332.
221.
MaricleRANuttJGValentineRJCarterJH. Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson’s disease: a double-blind, placebo-controlled study. Neurology. 1995;45(9):1757–1760.
222.
StarksteinSERobinsonRGLeiguardaRPreziosiTJ. Anxiety and depression in Parkinson’s disease. Behav Neurol. 1993;6(3):151–154.
223.
MenzaMARosenRC. Sleep in Parkinson’s disease. The role of depression and anxiety. Psychosomatics. 1995;36(3):262–266.
224.
RouthLCBlackJLAhlskogJE. Parkinson’s disease complicated by anxiety. Mayo Clin Proc. 1987;62(8):733–735.
225.
PontoneGMWilliamsJRAndersonKE. Anxiety and self-perceived health status in Parkinson’s disease. Parkinsonism Relat Disord. 2011;17(4):249–254.
226.
HannaKKCronin-GolombA. Impact of anxiety on quality of life in Parkinson’s disease. Parkinsons Dis. 2012;2012:640707.
227.
FosterPSDragoVYungRC. Anxiety affects working memory only in left hemibody onset Parkinson disease patients. Cogn Behav Neurol. 2010;23(1):14–18.
228.
PontoneGMWilliamsJRAndersonKE. Pharmacologic treatment of anxiety disorders in Parkinson disease. Am J Geriatr Psychiatry. 2013;21(6):520–528.
229.
HigginsonCIFieldsJATrösterAI. Which symptoms of anxiety diminish after surgical interventions for Parkinson disease?Neuropsychiatry Neuropsychol Behav Neurol. 2001;14(2):117–121.
230.
CastelliLPerozzoPZibettiMCrivelliBMorabitoULanotteMCossaFBergamascoBLopianoL. Chronic deep brain stimulation of the subthalamic nucleus for Parkinson’s disease: effects on cognition, mood, anxiety and personality traits. Eur Neurol. 2006;55(3):136–144.
231.
ChangCLiNWuY. Associations between bilateral subthalamic nucleus deep brain stimulation (STN-DBS) and anxiety in Parkinson’s disease patients: a controlled study. J Neuropsychiatry Clin Neurosci. 2012;24(3):316–325.
232.
KormosTC. Efficacy of rTMS in the treatment of co-morbid anxiety in depressed patients with Parkinson’s disease. Mov Disord. 2007;22(12):1836.
233.
MarinoLFriedmanJH. Letter to the editor: successful use of electroconvulsive therapy for refractory anxiety in Parkinson’s disease. Int J Neurosci. 2013;123(1):70–71.
234.
Dell’OssoBBuoliMBaldwinDSAltamuraAC. Serotonin norepinephrine reuptake inhibitors (SNRIs) in anxiety disorders: a comprehensive review of their clinical efficacy. Hum Psychopharmacol. 2010;25(1):17–29.
235.
SarathchandranPSomanSSarmaGKrishnanSKishoreA. Impulse control disorders and related behaviors in Indian patients with Parkinson’s disease. Mov Disord. 2013;28(13):1901–1902.
236.
CallesenMBWeintraubD2DamholdtMF3MøllerA. Impulsive and compulsive behaviors among Danish patients with Parkinson’s disease: prevalence, depression, and personality. Parkinsonism Relat Disord. 2014;20(1):22–26.
237.
FanWDingHMaJChanP. Impulse control disorders in Parkinson’s disease in a Chinese population. Neurosci Lett. 2009;465(1):6–9.
238.
AuyeungMTsoiTHTangWK. Impulse control disorders in Chinese Parkinson’s disease patients: the effect of ergot derived dopamine agonist. Parkinsonism Relat Disord. 2011;17(8):635–637.
239.
WeintraubDKoesterJPotenzaMN. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67(5):589–595.
240.
WuKPolitisMO’SullivanSS. Problematic Internet use in Parkinson’s disease. Parkinsonism Relat Disord. 2014;20(5):482–487.
241.
BonfantiABGattoEM. Kleptomania, an unusual impulsive control disorder in Parkinson’s disease?Parkinsonism Relat Disord. 2010;16(5):358–359.
242.
BienfaitKLMenzaMMarkMHDobkinRD. Impulsive smoking in a patient with Parkinson’s disease treated with dopamine agonists. J Clin Neurosci. 2010;17(4):539–540.
243.
JoutsaJMartikainenKVahlbergTKaasinenV. Effects of dopamine agonist dose and gender on the prognosis of impulse control disorders in Parkinson’s disease. Parkinsonism Relat Disord. 2012;18(10):1079–1083.
244.
KimJKimMKwon doY. Clinical characteristics of impulse control and repetitive behavior disorders in Parkinson’s disease. J Neurol. 2013;260(2):429–437.
245.
PolettiMLogiCLucettiC. A single-center, cross-sectional prevalence study of impulse control disorders in Parkinson disease: association with dopaminergic drugs. J Clin Psychopharmacol. 2013;33(5):691–694.
246.
RohdeKRiedelO, Lueken U, et al. [Impulsive-compulsive behaviours in a German Parkinson’s disease outpatient sample]. Fortschr Neurol Psychiatr. 2013;81(9):503–510.
247.
PontieriFEAssognaFPellicanoC. Sociodemographic, neuropsychiatric and cognitive characteristics of pathological gambling and impulse control disorders NOS in Parkinson’s disease. Eur Neuropsychopharmacol. 2015;25(1):69–76.
248.
HurtCSAlkufriFBrownRG. Motor phenotypes, medication and mood: further associations with impulsive behaviours in Parkinson’s disease. J Parkinsons Dis. 2014;4(2):245–254.
249.
WylieSAvan den WildenbergWRidderinkhofKRClaassenDOWootenGFManningCA. Differential susceptibility to motor impulsivity among functional subtypes of Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2012;83(12):1149–1154.
250.
ÁvilaACardonaXMartín-BaraneraMBelloJSastreF. Impulsive and compulsive behaviors in Parkinson’s disease: a one-year follow-up study. J Neurol Sci. 2011;310(1-2):197–201.
251.
WalshRALangAE. Multiple impulse control disorders developing in Parkinson’s disease after initiation of amantadine. Mov Disord. 2012;27(2):326.
252.
VitaleCSantangeloGErroRErricoDManganelliFImprotaIMocciaMBaroneP. Impulse control disorders induced by rasagiline as adjunctive therapy for Parkinson’s disease: report of 2 cases. Parkinsonism Relat Disord. 2013;19(4):483–484.
253.
JoutsaJMartikainenKVahlbergTVoonVKaasinenV. Impulse control disorders and depression in Finnish patients with Parkinson’s disease. Parkinsonism Relat Disord. 2012;18(2):155–160.
254.
JaakkolaEKaasinenVSiriC. Impulse control disorders are associated with multiple psychiatric symptoms in Parkinson’s disease. J Parkinsons Dis. 2014;4(3):507–515.
255.
PolettiMFrosiniDPagniC. Alexithymia is associated with impulsivity in newly-diagnosed, drug-naïve patients with Parkinson’s disease: an affective risk factor for the development of impulse-control disorders?J Neuropsychiatry Clin Neurosci. 2012;24(4):E36–E37.
256.
ScullinMKSollingerABLandJ. Sleep and impulsivity in Parkinson’s disease. Parkinsonism Relat Disord. 2013;19(11):991–994.
257.
KimYEJeonBSYangHJ. REM sleep behavior disorder: association with motor complications and impulse control disorders in Parkinson’s disease. Parkinsonism Relat Disord. 2014;20(10):1081–1084.
258.
FantiniMLMacedoLZibettiM. Increased risk of impulse control symptoms in Parkinson’s disease with REM sleep behaviour disorder. J Neurol Neurosurg Psychiatry. 2015;86(2):174–179.
259.
ValençaGTGlassPGNegreirosNN. Past smoking and current dopamine agonist use show an independent and dose-dependent association with impulse control disorders in Parkinson’s disease. Parkinsonism Relat Disord. 2013;19(7):698–700.
260.
BastiaensJDorfmanBJChristosPJNirenbergMJ. Prospective cohort study of impulse control disorders in Parkinson’s disease. Mov Disord. 2013;28(3):327–333.
261.
HälbigTDTseWFrisinaPGBakerBRHollanderEShapiroHTagliatiMKollerWCOlanowCW. Subthalamic deep brain stimulation and impulse control in Parkinson’s disease. Eur J Neurol. 2009;16(4):493–497.
262.
LimSYO’SullivanSSKotschetK. Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson’s disease. J Clin Neurosci. 2009;16(9):1148–1152.
263.
BallangerBvan EimerenTMoroE. Stimulation of the subthalamic nucleus and impulsivity: release your horses. Ann Neurol. 2009;66(6):817–824.
264.
WylieSARidderinkhofKREliasWJ. Subthalamic nucleus stimulation influences expression and suppression of impulsive behaviour in Parkinson’s disease. Brain. 2010;133(pt 12):3611–3624.
265.
Rodriguez-OrozMCLópez-AzcárateJGarcia-GarciaD. Involvement of the subthalamic nucleus in impulse control disorders associated with Parkinson’s disease. Brain. 2011;134(pt 1):36–49.
266.
DjamshidianAO’SullivanSSFoltynieT. Dopamine agonists rather than deep brain stimulation cause reflection impulsivity in Parkinson’s disease. J Parkinsons Dis. 2013;3(2):139–144.
267.
HackNAkbarUThompson-AvilaA. Impulsive and compulsive behaviors in Parkinson Study Group (PSG) centers performing deep brain stimulation surgery. J Parkinsons Dis. 2014;4(4):591–598.
268.
PlessowFFischerRVolkmannJSchubertT. Subthalamic deep brain stimulation restores automatic response activation and increases susceptibility to impulsive behavior in patients with Parkinson’s disease. Brain Cogn. 2014;87:16–21.
269.
CastriotoAFunkiewiezADebûB. Iowa gambling task impairment in Parkinson’s disease can be normalised by reduction of dopaminergic medication after subthalamic stimulation. J Neurol Neurosurg Psychiatry. 2015;86(2):186–190.
270.
CatalánMJde Pablo-FernándezEVillanuevaC. Levodopa infusion improves impulsivity and dopamine dysregulation syndrome in Parkinson’s disease. Mov Disord. 2013;28(14):2007–2010.
271.
Garcia-RuizPJMartinez CastrilloJCAlonso-CanovasA. Impulse control disorder in patients with Parkinson’s disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry. 2014;85(8):840–844.
272.
TortaDMCastelliLZibettiMLopianoLGeminianiG. On the role of dopamine replacement therapy in decision-making, working memory, and reward in Parkinson’s disease: does the therapy-dose matter?Brain Cogn. 2009;71(2):84–91.
273.
LeeJYKimJMKimJW. Association between the dose of dopaminergic medication and the behavioral disturbances in Parkinson disease. Parkinsonism Relat Disord. 2010;16(3):202–207.
274.
GiladiNWeitzmanNSchreiberSShabtaiHPeretzC. New onset heightened interest or drive for gambling, shopping, eating or sexual activity in patients with Parkinson’s disease: the role of dopamine agonist treatment and age at motor symptoms onset. J Psychopharmacol. 2007;21(5):501–506.
275.
IsaiasIUSiriCCiliaRDe GaspariDPezzoliGAntoniniA. The relationship between impulsivity and impulse control disorders in Parkinson’s disease. Mov Disord. 2008;23(3):411–415.
276.
MilenkovaM1MohammadiBKolleweK. Intertemporal choice in Parkinson’s disease. Mov Disord. 2011;26(11):2004–2010.
277.
DjamshidianAO’SullivanSSWittmannBCLeesAJAverbeckBB. Novelty seeking behaviour in Parkinson’s disease. Neuropsychologia. 2011;49(9):2483–2488.
278.
NombelaCRittmanTRobbinsTWRoweJB. Multiple modes of impulsivity in Parkinson’s disease. PLoS One. 2014;9(1):e85747.
279.
Rodríguez-ViolanteMGonzález-LatapiPCervantes-ArriagaACamacho-OrdoñezAWeintraubD. Impulse control and related disorders in Mexican Parkinson’s disease patients. Parkinsonism Relat Disord. 2014;20(8):907–910.
280.
AntoniniASiriCSantangeloG. Impulsivity and compulsivity in drug-naïve patients with Parkinson’s disease. Mov Disord. 2011;26(3):464–468.
281.
WeintraubDPapayKSiderowfA; Parkinson’s Progression Markers Initiative. Screening for impulse control symptoms in patients with de novo Parkinson disease: a case-control study. Neurology. 2013;80(2):176–180.
282.
VoonVGaoJBrezingC. Dopamine agonists and risk: impulse control disorders in Parkinson’s disease. Brain. 2011;134(pt 5):1438–1446.
283.
LeroiIBarracloughMMcKieS. Dopaminergic influences on executive function and impulsive behaviour in impulse control disorders in Parkinson’s disease. J Neuropsychol. 2013;7(2):306–325.
284.
BiundoRFormento-DojotPFacchiniS. Brain volume changes in Parkinson’s disease and their relationship with cognitive and behavioural abnormalities. J Neurol Sci. 2011;310(1-2):64–69.
285.
BiundoRWeisLFacchiniS. Patterns of cortical thickness associated with impulse control disorders in Parkinson’s disease. Mov Disord. 2015;30(5):688–695.
286.
AntonelliFKoJHMiyasakiJ. Dopamine-agonists and impulsivity in Parkinson’s disease: impulsive choices vs. impulsive actions. Hum Brain Mapp. 2014;35(6):2499–2506.
287.
RayNJMiyasakiJMZurowskiM. Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson’s patients with medication-induced pathological gambling: a [11C] FLB-457 and PET study. Neurobiol Dis. 2012;48(3):519–525.
288.
JoutsaJMartikainenKNiemeläS. Increased medial orbitofrontal [18F]fluorodopa uptake in Parkinsonian impulse control disorders. Mov Disord. 2012;27(6):778–782.
289.
RaoHMamikonyanEDetreJA. Decreased ventral striatal activity with impulse control disorders in Parkinson’s disease. Mov Disord. 2010;25(11):1660–1669.
290.
LeeJYSeoSHKimYK. Extrastriatal dopaminergic changes in Parkinson’s disease patients with impulse control disorders. J Neurol Neurosurg Psychiatry. 2014;85(1):23–30.
291.
VoonVRizosAChakravarttyR. Impulse control disorders in Parkinson’s disease: decreased striatal dopamine transporter levels. J Neurol Neurosurg Psychiatry. 2014;85(2):148–152.
292.
VriendCNordbeckAHBooijJ. Reduced dopamine transporter binding predates impulse control disorders in Parkinson’s disease. Mov Disord. 2014;29(7):904–911.
293.
DjamshidianAO’SullivanSSPapadopoulosA. Salivary cortisol levels in Parkinson’s disease and its correlation to risk behaviour. J Neurol Neurosurg Psychiatry. 2011;82(10):1107.
294.
YooHBLeeJYLeeJS. Whole-brain diffusion-tensor changes in parkinsonian patients with impulse control disorders. J Clin Neurol. 2015;11(1):42–47.
295.
PayerDEGuttmanMKishSJ. [11C]-(+)-PHNO PET imaging of dopamine D(2/3) receptors in Parkinson’s disease with impulse control disorders. Mov Disord. 2015;30(2):160–166.
296.
ZieglerDAAshourianPWonderlickJS. Motor impulsivity in Parkinson disease: associations with COMT and DRD2 polymorphisms. Scand J Psychol. 2014;55(3):278–286.
297.
LeeJYJeonBSKimHJParkSS. Genetic variant of HTR2A associates with risk of impulse control and repetitive behaviors in Parkinson’s disease. Parkinsonism Relat Disord. 2012;18(1):76–78.
298.
LeeJYLeeEKParkSS. Association of DRD3 and GRIN2B with impulse control and related behaviors in Parkinson’s disease. Mov Disord. 2009;24(12):1803–1810.
299.
HoenickaJGarcía-RuizPJPonceG. The Addiction-Related Gene ANKK1 in Parkinsonian Patients with Impulse Control Disorder. Neurotox Res. 2015;27(3):205–208.
300.
VallelungaAFlaibaniRFormento-DojotPBiundoRFacchiniSAntoniniA. Role of genetic polymorphisms of the dopaminergic system in Parkinson’s disease patients with impulse control disorders. Parkinsonism Relat Disord. 2012;18(4):397–399.
301.
BentivoglioARBaldoneroERicciardiLDe NigrisFDanieleA. Neuropsychological features of patients with Parkinson’s disease and impulse control disorders. Neurol Sci. 2013;34(7):1207–1213.
302.
PirayPZeighamiYBahramiFEissaAMHewediDHMoustafaAA. Impulse control disorders in Parkinson’s disease are associated with dysfunction in stimulus valuation but not action valuation. J Neurosci. 2014;34(23):7814–7824.
303.
DjamshidianAJhaAO’SullivanSS. Risk and learning in impulsive and nonimpulsive patients with Parkinson’s disease. Mov Disord. 2010;25(13):2203–2210.
304.
VoonVReynoldsBBrezingC. Impulsive choice and response in dopamine agonist-related impulse control behaviors. Psychopharmacology (Berl). 2010;207(4):645–659.
305.
PhuALXuZBrakouliasV. Effect of impulse control disorders on disability and quality of life in Parkinson’s disease patients. J Clin Neurosci. 2014;21(1):63–66.
306.
MamikonyanESiderowfADDudaJE. Long-term follow-up of impulse control disorders in Parkinson’s disease. Mov Disord. 2008;23(1):75–80.
307.
CarrièreNKreislerADujardinKDestéeADefebvreL. [Impulse control disorders in Parkinson’s disease: A cohort of 35 patients]. Rev Neurol (Paris). 2012;168(2):143–151
308.
BermejoPE. Topiramate in managing impulse control disorders in Parkinson’s disease. Parkinsonism Relat Disord. 2008;14(5):448–449.
309.
HicksCWPandyaMMItinIFernandezHH. Valproate for the treatment of medication-induced impulse-control disorders in three patients with Parkinson’s disease. Parkinsonism Relat Disord. 2011;17(5):379–381.
310.
BermejoPERuiz-HueteCAncionesB. Zonisamide in managing impulse control disorders in Parkinson’s disease. J Neurol. 2010;257(10):1682–1685.
311.
PapayKXieSXSternM. Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study. Neurology. 2014;83(9):826–833.
312.
OkaiDAskey-JonesSSamuelM. Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers. Neurology. 2013;80(9):792–799.
313.
DelaneyMSimpsonJLeroiI. Perceptions of cause and control of impulse control behaviours in people with Parkinson’s disease. Br J Health Psychol. 2012;17(3):522–535.
314.
MackJOkaiDBrownRG. The role of self-awareness and cognitive dysfunction in Parkinson’s disease with and without impulse-control disorder. J Neuropsychiatry Clin Neurosci. 2013;25(2):141–149.
315.
Dell’OssoBAltamuraACAllenAMarazzitiDHollanderE. Epidemiologic and clinical updates on impulse control disorders: a critical review. Eur Arch Psychiatry Clin Neurosci. 2006;256(8):464–475.
316.
VoonVSohrMLangAE. Impulse control disorders in Parkinson disease: a multicenter case--control study. Ann Neurol. 2011;69(6):986–996
317.
EkholmOEibergSDavidsenMHolstMLarsenCVJuelK. The prevalence of problem gambling in Denmark in 2005 and 2010: a sociodemographic and socioeconomic characterization. J Gambl Stud. 2014;30(1):1–10.
318.
DerbyshireKLGrantJE. Compulsive sexual behavior: A review of the literature. J Behav Addict. 2015;4(2):37–43.
319.
HoertelNLe StratYSchusterJPLimosinF. Gender differences in firesetting: results from the national epidemiologic survey on alcohol and related conditions (NESARC). Psychiatry Res. 2011;190(2-3):352–358.
320.
KoranLMFaberRJAboujaoudeELargeMDSerpeRT. Estimated prevalence of compulsive buying behavior in the United States. Am J Psychiatry. 2006;163(10):1806–12.
321.
ChambersRAPotenzaMN. Neurodevelopment, impulsivity, and adolescent gambling. J Gambl Stud. 2003;19(1):53–84.
322.
RayNJStrafellaAP. Imaging impulse control disorders in Parkinson’s disease and their relationship to addiction. J Neural Transm. 2013;120(4):659–664.
323.
HoppenbrouwersSSDe JesusDRStirpeT. Inhibitory deficits in the dorsolateral prefrontal cortex in psychopathic offenders. Cortex. 2013;49(5):1377–1385.
324.
LeemanRFPotenzaMN. A targeted review of the neurobiology and genetics of behavioural addictions: an emerging area of research. Can J Psychiatry. 2013;58(5):260–273.
325.
GrantJEOdlaugBLChamberlainSRHampshireASchreiberLRKimSW. A proof of concept study of tolcapone for pathological gambling: relationships with COMT genotype and brain activation. Eur Neuropsychopharmacol. 2013;23(11):1587–1596.
326.
StarksteinSEDragovicMDujardinK. Anxiety has specific syndromal profiles in Parkinson disease: a data-driven approach. Am J Geriatr Psychiatry. 2014;22(12):1410–1417.
327.
FernandezHHAarslandDFénelonG. Scales to assess psychosis in Parkinson’s disease: Critique and recommendations. Mov Disord. 2008;23(4):484–500.
328.
RieuIMartinez-MartinPPereiraB. International validation of a behavioral scale in Parkinson’s disease without dementia. Mov Disord. 2015; 30(5):705–713.
329.
LevyRDuboisB. Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits. Cereb Cortex. 2006;16(7):916–928.
330.
YathamLNKennedySHParikhSV. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013;15(1):1–44.
